A Phase 2 interventional study of Knee Pain Ejiao Paste and Knee Pain Ejiao-free Clear Paste in Knee Osteoarthritis, sponsored by ShuGuang Hospital. Enrolling by invitation at 2 sites in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-05.
Sponsored by ShuGuang Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 136 studies in Osteoarthritis, Knee with a site in China — 32 open to participants now, 32 under way, 4 of them phase 3. Osteoarthritis, Knee · China.
Among the 136 studies in Osteoarthritis, Knee with a site in China, this one is the 71st largest by planned enrollment of the 115 interventional ones that give a count, is one of 12 that started in 2026, is one of 9 in phase 2, reaches primary completion later than 18 of the 31 other live ones, and was the 125th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →32 of the 136 studies in Osteoarthritis, Knee with a site in China are open now. Recruiting first, the newest first:
Hangzhou Sciwind Biosciences Co., Ltd. · Sites in China
Ages 18–75
China-Japan Friendship Hospital · Sites in China
Ages 18–65
The First Affiliated Hospital of Xinxiang Medical College · Sites in China
Ages 18–65
Belief BioMed (Beijing) Co., Ltd · Sites in China
Ages 40–75
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 40–70
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
136 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 15 · Phase 3 15 · Phase 4 15
First in 2000; this study’s year is marked. 12 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 100 across the 115 interventional studies, 136 across the 21 observational. Of the 53 that completed or were terminated, 6 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 136 have an industry lead sponsor. The 10 most frequent:
ShuGuang Hospital is the lead sponsor of 18 studies on the registry; 2 are open to participants now.
ShuGuang Hospital has 1 study filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
10 of the studies in Osteoarthritis, Knee with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06570291Phase 3Wuxi Cellular Biopharmaceutical Group Ltd.Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis | 2026-12 |
| NCT07868224Jiangxi University of Traditional Chinese MedicineValidating Blinding Maintenance of a Sham-Sensitization Control Design for Sensitization Acupuncture Trials | 2026-12-01 |
| NCT07504562ShuGuang HospitalKnee Pain Ejiao Paste for Knee Osteoarthritis | 2026-12-31 |
| NCT03383081Sclnow Biotechnology Co., Ltd.The Safety/Efficacy of hUC Mesenchymal Stem Cells(19#iSCLife®-OA) Therapy for Patients With Osteoarthritis | 2026-12-31 |
| NCT06010979Tian HuaClinical Cohort Study of Knee Arthroplasty Assisted by Digital Technology | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 136 studies in Osteoarthritis, Knee with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To explore the analgesic efficacy of Knee Pain Ejiao Paste in the treatment of knee osteoarthritis (Qi and Blood Deficiency Pattern) after 12 weeks, using an Ejiao-free clear paste as a parallel control and incorporating a synthetic external control.
Overall Design: This study employs a randomized, double-blind, internal and external dual-control clinical trial design. Trial Procedures: The trial consists of a screening/baseline period and a 12-week treatment period, with an End-of-Study (EOS) or End-of-Treatment (EOT) visit conducted after 12 weeks of administration. Randomization and Blinding: A stratified block randomization method will be used to assign participants to each group in a 1:1 ratio, with competitive enrollment across all centers and a double-blind design. External Control: Literature-based data. Data Collection: Electronic Data Capture (EDC) system and Electronic Patient-Reported Outcome (ePRO) system.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Knee Pain Ejiao Paste: Oral administration, 1 bag per dose, twice daily (20g per dose); Composition: Xi Yang Shen (Panacis Quinquefolii Radix, 260g), Long Yan Rou (Arillus Longan, 1300g), Shan Yao (Dioscoreae Rhizoma, 1300g), and E Jiao (Colla Corii Asini, 350g); Instruction: It is recommended to take the medication at a fixed time each day.
Drug: Knee Pain Ejiao Paste
Knee Pain Ejiao-free Clear Paste: Oral administration, 1 bag per dose, twice daily (20g per dose); Composition: Xi Yang Shen (Panacis Quinquefolii Radix, 260g), Long Yan Rou (Arillus Longan, 1300g), Shan Yao (Dioscoreae Rhizoma, 1300g), and Mu Tang Chun (Xylitol, 350g)
Drug: Knee Pain Ejiao-free Clear Paste
By comparing Knee Pain Ejiao Paste with the base formula, Knee Pain Ejiao-free Clear Paste, this study minimizes confounding factors such as dosage form, administration method, and matrix components. This approach allows for a precise evaluation of the incremental therapeutic benefits contributed by the addition of Ejiao, thereby providing direct evidence for the medicinal value of Colla Corii Asini.
Using an Ejiao-free clear paste as a parallel control.
Change from baseline in Numerical Rating Scale (NRS) score for target knee pain at Week 12
Selection of the target knee joint: For participants with unilateral involvement, the affected knee is designated as the target knee. In cases of bilateral involvement, the knee with the higher Numerical Rating Scale (NRS) pain score will be selected as the target knee. If the pain NRS scores are identical for both knees, the right knee joint will be chosen as the target knee.
Time frame: Screening Period/Baseline, Week 12
Patient Electronic Diary (ePRO) Joint Pain NRS Score
During the treatment period, subjects will complete the NRS score for target knee pain and other records on ePRO daily.
Time frame: Baseline to Week 12
Change from baseline in NRS score for target knee pain at Weeks 4 and 8
Selection of the target knee joint: For participants with unilateral involvement, the affected knee is designated as the target knee. In cases of bilateral involvement, the knee with the higher Numerical Rating Scale (NRS) pain score will be selected as the target knee. If the pain NRS scores are identical for both knees, the right knee joint will be chosen as the target knee.
Time frame: Screening Period/Baseline, Week 4, and Week 8
Pain relief rate of target knee pain at Weeks 4, 8, and 12 post-treatment
Effectiveness is defined as a ≥ 50% decrease in the target knee pain NRS score relative to baseline, where the reduction rate = \[(Pre-trearment score - Post-treatment score) ÷ Pre-trearment score\] × 100%.
Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12
Time to onset of target knee pain relief
Time (in days) to the first ≥ 25% reduction from baseline in target knee pain NRS score (as recorded in the diary card).
Time frame: Baseline to Week 12
Change from baseline in WOMAC total score for the target knee at Weeks 4, 8, and 12 post-treatment
Comparison of the change from baseline in WOMAC total score between groups at Weeks 4, 8, and 12 post-treatment.
Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12
Changes from baseline in WOMAC subscale scores (Pain, Stiffness, and Physical Function) for the target knee at Weeks 4, 8, and 12 post-treatment
Comparison of the change from baseline in WOMAC subscale scores (Pain, Stiffness, and Physical Function) between groups at Weeks 4, 8, and 12 post-treatment.
Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12
Comparison of MOAKS scores for joint effusion in the target knee at Week 12 post-treatment
Comparison of the change from baseline in MOAKS joint effusion scores between groups at Week 12 post-treatment.
Time frame: Screening Period/Baseline, Week 12
Change from baseline in subject satisfaction scores at Week 12 post-treatment
Comparison of the change from baseline in subject satisfaction scores between groups at Weeks 4, 8, and 12, as well as the proportion of satisfied subjects between groups.
Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12
Change from baseline in investigator satisfaction scores at Week 12 post-treatment
Comparison of the change from baseline in investigator satisfaction scores between groups at Weeks 4, 8, and 12 post-treatment, as well as the proportion of investigator-rated satisfaction between groups.
Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12
Consumption of rescue medication during the treatment period
Comparison of the consumption of Celecoxib tablets as rescue medication between groups during the study period.
Time frame: Baseline to Week 12
Effective rate of TCM syndrome at Weeks 4, 8, and 12 post-treatment
Comparison of the between-group differences in the effective rate at Weeks 4, 8, and 12 post-treatment. Based on the results of the TCM Syndrome Quantitative Rating Scale, TCM syndrome scores are calculated before and after treatment, and the efficacy is evaluated according to the following criteria: Effective: A reduction in TCM syndrome score of ≥ 50% Ineffective: A reduction in TCM syndrome score of less than 50% The reduction rate of TCM syndrome score is caculated as: Reduction Rate = \[(Pre-trearment score - Post-treatment score) ÷ Pre-trearment score\] × 100%.
Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12
Changes from baseline in TCM syndrome total scores and individual symptom scores at Weeks 4, 8, and 12 post-treatment
Comparison of the change from baseline in TCM syndrome total scores and individual symptom scores between groups at Weeks 4, 8, and 12 post-treatment.
Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12
Adverse Event (AE)
Adverse events will be evaluated and recorded based on their type, incidence, severity, timing, and causality (relationship to the study drug).
Time frame: Week 4, Week 8, and Week 12
Vital Signs (Body Temperature)
Body temperature (°C) is measured under standardized conditions (rest ≥5 minutes, using calibrated equipment) by trained study personnel.
Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12
Vital Signs (Pulse Rate)
Pulse rate (beats per minute, bpm) is measured under standardized conditions (rest ≥5 minutes, using calibrated equipment) by trained study personnel.
Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12
Vital Signs (Respiratory Rate)
Respiratory rate (breaths per minute) is measured under standardized conditions (rest ≥5 minutes, using calibrated equipment) by trained study personnel.
Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12
Vital Signs (Blood Pressure)
Blood pressure (systolic and diastolic, mmHg) is measured under standardized conditions (rest ≥5 minutes, using calibrated equipment) by trained study personnel. Both systolic blood pressure (SBP) and diastolic blood pressure (DBP) are recorded and reported separately.
Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12
Laboratory Parameters (Hematology-Red Blood Cell count)
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Hematology (Blood Routine): Red Blood Cell count (RBC) Unit: ×10¹²/L (Number of red blood cells per liter of blood × 10¹²)
Time frame: Screening Period/Baseline, Week 12
Laboratory Parameters (Hematology-White Blood Cell count)
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Hematology (Blood Routine): White Blood Cell count (WBC) Unit: ×10⁹/L (Number of white blood cells per liter of blood × 10⁹)
Time frame: Screening Period/Baseline, Week 12
Laboratory Parameters (Hematology- Platelet count)
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Hematology (Blood Routine): Platelet count (PLT) Unit: ×10⁹/L (Number of platelets per liter of blood × 10⁹)
Time frame: Screening Period/Baseline, Week 12
Laboratory Parameters (Hematology-Hemoglobin )
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Hematology (Blood Routine): Hemoglobin (HGB)-Hemoglobin Concentration Unit: g/L (grams per liter) or g/dL
Time frame: Screening Period/Baseline, Week 12
Laboratory Parameters (Hematology-Neutrophil percentage )
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Hematology (Blood Routine): Neutrophil percentage (NEUT%) Unit: % (Percentage of neutrophils among total white blood cells)
Time frame: Screening Period/Baseline, Week 12
Laboratory Parameters (Liver Function-Alanine Aminotransferase)
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Liver Function: Alanine Aminotransferase (ALT) Unit: U/L (units per liter)
Time frame: Screening Period/Baseline, Week 12
Laboratory Parameters (Liver Function- Aspartate Aminotransferase)
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Liver Function: Aspartate Aminotransferase (AST) Unit: U/L (units per liter)
Time frame: Screening Period/Baseline, Week 12
Laboratory Parameters (Liver Function-Total Bilirubin)
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Liver Function: Total Bilirubin (TBIL) Unit: μmol/L (micromoles per liter)
Time frame: Screening Period/Baseline, Week 12
Laboratory Parameters (Liver Function-Alkaline Phosphatase)
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Liver Function:Alkaline Phosphatase (ALP) Unit: U/L (units per liter)
Time frame: Screening Period/Baseline, Week 12
Laboratory Parameters (Liver Function-γ-Glutamyl Transferase)
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Liver Function: γ-Glutamyl Transferase (GGT) Unit: U/L (units per liter)
Time frame: Screening Period/Baseline, Week 12
Laboratory Parameters (Renal Function- Serum Creatinine )
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Renal Function: Serum Creatinine (Scr) Unit: μmol/L (micromoles per liter) or mg/dL
Time frame: Screening Period/Baseline, Week 12
Laboratory Parameters (Renal Function- Blood Urea Nitrogen)
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Renal Function: Blood Urea Nitrogen (BUN) / Urea Unit: mmol/L (millimoles per liter) or mg/dL
Time frame: Screening Period/Baseline, Week 12
Laboratory Parameters (Renal Function- Estimated Glomerular Filtration Rate)
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Renal Function: Estimated Glomerular Filtration Rate (eGFR) Unit: mL/min/1.73m² (milliliters per minute per 1.73 square meters)
Time frame: Screening Period/Baseline, Week 12
Laboratory Parameters (Renal Function- Urine Albumin-Creatinine Ratio)
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Renal Function: Urine Albumin-Creatinine Ratio (UACR) Unit: mg/g (milligrams per gram) or mg/mmol
Time frame: Screening Period/Baseline, Week 12
Laboratory Parameters (Urinalysis-Protein )
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Urinalysis (Urine Routine): Protein (PRO) Unit: Qualitative/Semi-quantitative, typically reported as: Negative (-), Trace (±), +, ++, +++, ++++ (or mg/dL, g/L)
Time frame: Screening Period/Baseline, Week 12
Laboratory Parameters (Urinalysis-Glucose )
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Urinalysis (Urine Routine): Glucose (GLU) Unit: Qualitative/Semi-quantitative, typically reported as: Negative (-), Trace (±), +, ++, +++, ++++ (or mmol/L, mg/dL)
Time frame: Screening Period/Baseline, Week 12
Laboratory Parameters (Urinalysis-Red Blood Cells)
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Urinalysis (Urine Sediment Microscopy): Red Blood Cells (RBC) Unit: per high-power field (/HPF) or per microliter (μL) (microscope count)
Time frame: Screening Period/Baseline, Week 12
Laboratory Parameters (Urinalysis-Leukocytes)
Laboratory tests are performed as part of routine safety monitoring to evaluate potential hematological, hepatic, renal, or urinary effects of the investigational treatment. Urinalysis (Urine Routine): Leukocytes (LEU) Unit: per high-power field (/HPF) or per microliter (μL) (microscope count)
Time frame: Screening Period/Baseline, Week 12
Blood Glucose
Measuring Fasting Blood Glucose (FBG), which is the blood glucose level measured after fasting for 8 to 12 hours.
Time frame: Screening Period/Baseline, Week 12
Blood Lipids
Measuring fasting Total Cholesterol (TC), Low-Density Lipoprotein Cholesterol (LDL-C), High-Density Lipoprotein Cholesterol (HDL-C), and Triglycerides (TG).
Time frame: Screening Period/Baseline, Week 12
Heart Rate on 12-lead electrocardiogram
Heart rate (beats per minute) is measured from a standard 12-lead electrocardiogram recorded after at least 5 minutes of rest in a supine position, using calibrated equipment. Measurements are performed by trained personnel and interpreted by qualified investigators or cardiologists. Unit of Measure: beats per minute (bpm)
Time frame: Screening Period/Baseline, Week 12
PR Interval on 12-lead electrocardiogram
PR interval (milliseconds) is measured from a standard 12-lead electrocardiogram recorded after at least 5 minutes of rest in a supine position, using calibrated equipment. Measurements are performed by trained personnel and interpreted by qualified investigators or cardiologists. Unit of Measure: milliseconds (ms)
Time frame: Screening Period/Baseline, Week 12
QRS Duration on 12-lead electrocardiogram
QRS duration (milliseconds) is measured from a standard 12-lead electrocardiogram recorded after at least 5 minutes of rest in a supine position, using calibrated equipment. Measurements are performed by trained personnel and interpreted by qualified investigators or cardiologists. Monitored for potential ventricular conduction abnormalities. Unit of Measure: milliseconds (ms)
Time frame: Screening Period/Baseline, Week 12
QT Interval on 12-lead electrocardiogram
QT interval (milliseconds) is measured from a standard 12-lead electrocardiogram recorded after at least 5 minutes of rest in a supine position, using calibrated equipment. Measurements are performed by trained personnel and interpreted by qualified investigators or cardiologists. Unit of Measure: milliseconds (ms)
Time frame: Screening Period/Baseline, Week 12
Corrected QT Interval (QTc) on 12-lead electrocardiogram
Corrected QT interval (QTc, milliseconds) is calculated from the QT interval on a standard 12-lead electrocardiogram (recorded after ≥5 minutes rest, supine position, calibrated equipment) using Bazett or Fridericia formula as specified in the protocol. Interpreted by qualified cardiologists or trained investigators. Unit of Measure: milliseconds (ms)
Time frame: Screening Period/Baseline, Week 12
Pharmacokinetic (PK) Parameters-Plasma Maximum Observed Concentration (Cmax)
Plasma concentration measured from blood samples collected at Baseline, Weeks 4, 8, and 12( or early out of study).The exact time of blood collection and the time of the dose most recent to the collection must be recorded for each visit. Cmax is the maximum observed concentration post-dose. Parameters estimated using non-compartmental analysis or population PK modeling due to sparse sampling. Geometric mean and variability reported. Assessed as an exploratory pharmacokinetic biomarker. Unit of Measure: ng/mL (or appropriate unit, e.g., nmol/L)
Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12
Pharmacokinetic (PK) Parameters-Plasma Trough Concentration (Ctrough)
Plasma concentration measured from blood samples collected at Baseline, Weeks 4, 8, and 12( or early out of study).The exact time of blood collection and the time of the dose most recent to the collection must be recorded for each visit. Ctrough is the observed minimum concentration at the end of the dosing interval. Reported as geometric mean and variability. Exploratory pharmacokinetic endpoint focusing on steady-state trough exposure. Unit of Measure: ng/mL (or nmol/L, adjust based on drug)
Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12
Pharmacokinetic (PK) Parameters-Time Curve (AUC0-last)
Area under the concentration-time curve from time zero to the last measurable concentration (AUC0-last), estimated using population PK methods. Geometric mean reported. Exploratory PK biomarker of exposure. Unit of Measure: h·ng/mL (or appropriate, e.g., h·nmol/L)
Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12
Gut Microbial Alpha-diversity
Evaluation of microbial richness and evenness within fecal samples using 16S rRNA sequencing. Alpha-diversity represents the biological variety within a single sample. Unit of Measure: Shannon Diversity Index (a calculated score typically ranging from 0 to 5, where higher values indicate greater diversity).
Time frame: Screening Period/Baseline, Week 12
Gut Microbial Relative Abundance
Assessment of the taxonomic composition of the gut microbiota at the genus and species levels via metagenomic sequencing. Unit of Measure: Percentage of total sequences (%).
Time frame: Screening Period/Baseline, Week 12
Fecal Metabolomic Profiles
Untargeted metabolomics analysis using LC-MS/GC-MS to identify global metabolic shifts and differential metabolites induced by the treatment. Unit of Measure: Normalized peak intensity (arbitrary units).
Time frame: Screening Period/Baseline, Week 12
Fecal Short-Chain Fatty Acid (SCFA)
Quantitative analysis of major SCFAs (acetate, propionate, and butyrate) using GC-MS. The sum of these concentrations will be reported. Unit of Measure: μ mol/g of feces.
Time frame: Screening Period/Baseline, Week 12
Plasma Concentration of Cartilage Oligomeric Matrix Protein (COMP)
Evaluation of cartilage turnover and degradation levels. COMP is a key structural protein of the cartilage matrix, and its plasma concentration reflects the rate of cartilage breakdown in patients with knee osteoarthritis. Measured using Enzyme-Linked Immunosorbent Assay (ELISA). Unit of Measure: ng/mL
Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12
Plasma Level of C-Terminal Cross-Linked Telopeptide of Type II Collagen (CTX-II)
Assessment of cartilage collagen degradation. CTX-II is a specific biomarker for the degradation of type II collagen, the primary collagen found in articular cartilage. Higher levels are associated with increased radiographic progression of knee osteoarthritis. Measured using high-sensitivity immunoassay. Unit of Measure: pg/mL
Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12
Plasma Concentration of Tryptophan
Assessment of systemic amino acid metabolism and inflammatory signaling. Tryptophan is an essential amino acid whose metabolic pathways (such as the kynurenine pathway) are often altered by chronic inflammation in knee osteoarthritis. Changes in tryptophan levels can reflect the metabolic impact of treatment on systemic inflammation and pain-related pathways. Measured using Liquid Chromatography-Mass Spectrometry (LC-MS). Unit of Measure: nmol/L
Time frame: Screening Period/Baseline, Week 4, Week 8, and Week 12
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.
Of 43 non-industry phase 2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 61. This study's planned 9 months is below that.
Counting every sponsor, half of 101 studies reached it within 20 months; a quarter within 12 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ShuGuang Hospital